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Letter to the Editor 
Platelet indices evaluation in patients with liver cirrhosis: methodological drawbacks
I read the article documented by Xianghong et al. with great interest1. They assessed the mean platelet volume 
(MPV), platelet count and  P selectin (CD62 P) expression in liver cirrhosis. The values of  CD62P and MPV in 
patients with cirrhosis were significantly higher than those of  the control group, while the platelet count values 
were significantly lower than those of  the control group. This study gives important information on this clinically 
relevant condition and thanks to the authors for their contribution. However, I want to bring to attention some 
drawbacks in methodology.
The basically MPV measurement method is correct. On the other hand, it must not be forgotten that cardiovas-
cular dieases and many cardiovascular risk factors like, obesity, hypertension, smoking, hyperlipidemia, diabetes 
mellitus, prediabetes, atrial fibrillation, metabolic syndrome, fatty liver disease affect MPV values2,3. In addition 
rheumatic and inflammatory chronic diseases also affect MPV values3. They included heart diseases, brain dis-
eases, acute infections and diabetes mellitus. However, they didn’t mention about the body mass index, smoking 
status, blood pressure levels, blood lipid levels, metabolic syndrome and rhythm status in patients and controls. 
It has been shown that smoking, obesity, hyperlipidemia, hypertension, metabolic syndrome and atrial fibrillation 
increase MPV values. It is clear that, these factors should be taken into account for accurate MPV assessment. It 
would have been better if  the authors had given this information.
The MPV is a measurement of  the platelet volume that is included within full blood count parameters. When 
compared with smaller ones, larger platelets aggregate more rapidly with collagen, have more granules, express 
more glycoprotein Ib and IIb/IIIa receptors and moreover have higher thromboxane A2 level2,3. Previous studies 
showed that many cardiovascular risk factors and cardiovascular diseases can affect MPV. Due to this all con-
founding factors should be taken into account. If  the MPV measurement is main goal in related studies, maximum 
effort must be provided in consideration of  confounding factors in MPV analysis.
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